Cell Line Data Sheet for SMS-KANR

Disease:	Neuroblastoma
Phase of Therapy:	Post-Chemotherapy (Progressive Disease)
Treatment:	Cyclophosphamide, doxorubicin, radiation therapy
Disease Stage:	4
Gender:	Female
Age at diagnosis:	36 months
Race:	N/A
Age at sample collection:	N/A
Source of Culture:	Bone Marrow
Primary Tumor Site:	Pelvis
Date Established:	October 1978
MYCN Patient:	Amplified
MYCN Cell line:	N/A
TH mRNA:	Positive
p53 functionality:	Functional
Telomere Mechanism	N/A
ALK:	WT

IC90 (DIMSCAN*):
***see reference 4**

CBDCA (µg/ml)	CDDP (µg/ml)	DOX (ng/ml)	ETOP (ng/ml)	L-PAM (µg/ml)
1.3	0.8	45.7	45.7	5.6

CBDCA, carboplatin; CDDP, cisplatin; DOX, doxorubicin; ETOP, etoposide; L-PAM, melphalan

Growth Conditions: Please see Protocols section at https://www.cccells.org/protocols.php
5% CO_2, 20% O_2, 37.0°C

Media Formulation: Please see Protocols section at https://www.cccells.org/protocols.php
Cells are grown in a base medium of Iscove's Modified Dulbecco's Medium plus the following supplements (to a final concentration): 20% Fetal Bovine Serum, 4mM L-Glutamine, 1X ITS (5 µg/mL insulin, 5 µg/mL transferrin, 5 ng/mL selenous acid)

Doubling Time: 69 hours
Growth Properties: Round, teardrop-shaded neuroblasts, adherent and suspended cells, grow mostly in clumps

STR Profile: May be obtained at https://strdb.cccells.org/

Notes: The Childhood Cancer Repository has a matching cell line available from this same patient – SMS-KAN.

All COG Repository cell lines are antibiotic-free, mycoplasma-free, and cryopreserved in 50% FBS / 7.5% DMSO. Each vial label contains the cell line name, passage number, total viable cell count (usually 5-10e6), the overall cell viability, and date frozen. All cell lines are validated with original patient sample by STR analysis.

Cell Line Data Sheet for SMS-KANR

References:

1. Reynolds CP, Biedler JL, Spengler BA, Reynolds DA, Ross RA, Frenkel EP, Smith RG: Characterization of human neuroblastoma cell lines established before and after therapy. J Natl Cancer I. 76:375-387, 1986. PubMed ID: 3546456
https://www.sciencedirect.com/science/article/pii/S0002817787420187?via%3Dihub

2. Reynolds CP, Brodeur GM, Tomayko MM, Donner L, Helson L, Seeger RC, Triche TJ: Biological classification of cell lines derived from human extra-cranial neural tumors. Prog Clin Biol Res.271:291-306, 1988. PubMed ID: 3406003
https://pubmed.ncbi.nlm.nih.gov/3406003/

3. Keshelava N, Seeger RC, Groshen S, Reynolds CP: Drug resistance patterns of human neuroblastoma cell lines derived from patients at different phases of therapy. Cancer Research. 58:5396-5405, 1998. PubMed ID: 9850071
https://cancerres.aacrjournals.org/content/58/23/5396.long

4. Keshelava N, Groshen S, Reynolds CP. Cross-resistance of topoisomerase I and II inhibitors in neuroblastoma cell lines. Cancer Chemoth Pharm. 45: 1-8, 2000. PubMed ID: 10647494
https://link.springer.com/article/10.1007%2FPL00006736

5. Frgala T, Kalous O, Proffitt RT, Reynolds CP: A novel cytotoxicity assay with a 4 log dynamic range that identifies synergistic drug combinations. Mol Cancer Ther. 6:886-89, 2007. PubMed ID: 17363483
https://mct.aacrjournals.org/content/6/3/886.long

6. Kang MH, Smith MA, Morton CL, Keshlava N, Houghton PJ, Reynolds CP. National Cancer Institute Pediatric Preclinical Testing Program: Model Description for In Vitro Cytotoxicity Testing. Pediatr Blood Cancer. 56: 239-249, 2011. PubMed ID: 20922763 (www.PPTPinvitro.org)
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3005554/

Cell Line Data Sheet for SMS-KANR

Cell Line Name: **SMS-KANR**

Low confluency (10x magnification)

High confluency (10x magnification)

Low confluency (20x magnification)

High confluency (20x magnification)